LY-311727 (3-30 mg/kg; i.v.) dramatically suppresses the circulating enzyme activity in mice with Mt-sPLA2 transgenic the intravenous (i.v.) administration[2]. Animal Model: C57BL/6J mice, metallothionein promoter-human secretory PLA2 minigene (Mt-sPLA2) transgenic mice model[2] Dosage: 3 mg/kg, 10 mg/kg, 30 mg/kg Administration: Intravenous injection Result: Significantly and dose dependently suppressed the PLA2 activity in the serum.
In Vitro
LY-311727 (0.1-10 μM) suppresses the contractile responses induced by human non-pancreatic secretory phospholipase A2 (hnps-PLA2), in a concentration related manner[1]. LY-311727 nearly abolishes the hnps-PLA2 responses at 1μM, while it failed to suppress porcine pancreatic PLA2 concentration response curves at the same concentration[1]. LY-311727 displays 1,500-fold selectivity when assayed against porcine pancreatic s-PLA2[1].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. R W Schevitz, et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol. 1995 Jun;2(6):458-65.
[2]. N Fox, et al. Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitors. Eur J Pharmacol. 1996 Jul 18;308(2):195-203.
[3]. M Murakami, et al. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem. 1998 Jun 5;273(23):14411-23.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
